Breaking News Instant updates and real-time market news.

AGN

Allergan

$227.94

3.95 (1.76%)

, TBRA

Tobira Therapeutics

$40.28

0.18 (0.45%)

08:01
10/19/16
10/19
08:01
10/19/16
08:01

Allergan, Tobira Therapeutics announce early termination of HSR waiting period

Allergan (AGN) and Tobira Therapeutics (TBRA) announced that the U.S. Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended, with respect to Allergan's pending acquisition of Tobira. The early termination of the HSR waiting period satisfies one of the conditions to the closing of the pending acquisition, which remains subject to other customary closing conditions. Both companies expect the transaction to be completed by the end of 2016.

AGN

Allergan

$227.94

3.95 (1.76%)

TBRA

Tobira Therapeutics

$40.28

0.18 (0.45%)

  • 26

    Oct

  • 02

    Nov

  • 06

    Nov

AGN Allergan
$227.94

3.95 (1.76%)

09/21/16
GABE
09/21/16
NO CHANGE
GABE
Buy
Gabelli questions if Allergan could target Gilead next
Gabelli analyst Kevin Kedra said that "like most" he was surprised at the price paid and the strategic fit of Allergan's (AGN) deal to buy Tobira Therapeutics (TBRA), but wonders if Allergan CEO Brent Saunders is "playing chess while the market is playing checkers" and could be preparing a bid for Gilead (GILD). After Allergan's "very loud statement about its commitment to NASH and liver disease," a deal for Gilead, the leading company in liver disease and "one of the cheapest companies in pharma/biotech," would appear to make more sense, Kedra tells investors, adding that an acquisition of Gilead at a price of $115 per share would be "highly accretive" for Allergan. The analyst keeps a Buy rating on Allergan shares.
09/22/16
BERN
09/22/16
NO CHANGE
BERN
Allergan acquisitions positive, says Bernstein
After Allergan bought two companies with NASH drugs and the stock fell, Bernstein analyst Aaron Gal says the acquisitions were viewed as expensive. Gal says "it makes almost no difference" if the deals were expensive, as the important issue is whether the products succeed. He believes that the market would never penalize Roche or Celgene for similar deals, and he thinks this indicates that Allergan is "misvalued." He says that Allergan is his "high conviction buy" stock and keeps a $335 price target on the shares.
09/26/16
LEER
09/26/16
NO CHANGE
LEER
Shire Xiidra launch to 'significantly' expand dry eye category, says Leerink
Leerink analyst Jason Gerberry remains optimistic that Shire's (SHPG) Xiidra launch will "significantly" expand the category for dry eye disease brands, while not meaningfully eroding Allergan's (AGN) Restasis market leading position. While it's still early in the launch of Xiidra and payer access remains a critical variable, the analyst does not anticipate access being a major barrier. Gerberry reiterates an Outperform rating on both Shire and Allergan's shares.
10/14/16
LEER
10/14/16
NO CHANGE
Target $294
LEER
Outperform
Leerink positive on Allergan ahead of Restasis patent decision
Leerink analyst Jason Gerberry is positive on Allergan's franchise outlook as he believes the company will either maintain a double-digit top-line" growth pharma" trajectory or alternatively institute a dividend, and will prevail in the ongoing Restasis patent challenge. Gerberry likes Allergan's underlying growth trends of the gastro and derm franchises and pipeline optionality, and reiterates an Outperform rating and $294 price target on the shares.
TBRA Tobira Therapeutics
$40.28

0.18 (0.45%)

09/20/16
STFL
09/20/16
NO CHANGE
Target $6
STFL
Buy
Stifel says Conatus emricasan an interesting asset amid increased focus on NASH
Following Allergan's (AGN) acquisition of small-cap NASH play Tobira (TBRA), Stifel analyst Stephen Willey notes there are some "interesting" similarities between Conatus (CNAT) and the latter. However, the analyst points out that the clearest distinctions between the two are Conatus' emphasis on some of the downstream consequences of NASH fibrosis and the amount of meaningful clinical data generated to date. Willey still thinks Conatus' emricasan is an interesting asset, but urges investors seeking Tobira-like premiums to exercise a level of caution. He reiterates a Buy rating and $6 price target on Conatus' shares. In afternoon trading, shares of Conatus have gained about 20% to $2.10.
09/21/16
BARD
09/21/16
NO CHANGE
Target $332
BARD
Outperform
Intercept undervalued based on Allergan's upfront payment for Tobira, says Baird
Baird analyst Brian Skorney is positive on the yesterday's merger activity in the NASH space, specifically Allergan's (AGN) offer to buy Tobira Therapeutics (TBRA). Based on the upfront payment to Tobira from Allergan, Skorney said he can't help but question whether Intercept (ICPT) shares are undervalued. Skorney reiterated his Outperform rating on Intercept shares and keeps a $332 price target on the stock.
09/21/16
CANT
09/21/16
DOWNGRADE
CANT
Hold
Tobira Therapeutics downgraded to Hold from Buy at Cantor
Cantor analyst Elemer Piros downgraded Tobira (TBRA) after the company agreed to be acquired by Allergan (AGN). Target to $42 from $19.

TODAY'S FREE FLY STORIES

MITL

Mitel

06:34
02/23/17
02/23
06:34
02/23/17
06:34
Earnings
Mitel reports Q4 adjusted EPS 25c, consensus 23c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 07

    Mar

TFX

Teleflex

$184.01

-0.51 (-0.28%)

06:34
02/23/17
02/23
06:34
02/23/17
06:34
Earnings
Teleflex reports Q4 adjusted EPS $2.13, consensus $2.09 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

DORM

Dorman Products

$77.94

5.68 (7.86%)

06:34
02/23/17
02/23
06:34
02/23/17
06:34
Downgrade
Dorman Products rating change  »

Dorman Products…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZBRA

Zebra Technologies

$85.73

-0.95 (-1.10%)

06:33
02/23/17
02/23
06:33
02/23/17
06:33
Earnings
Zebra Technologies reports Q4 EPS $1.93, consensus $1.73 »

Reports Q4 revenue $942M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

WAAS

AquaVenture

$18.01

0.69 (3.98%)

06:33
02/23/17
02/23
06:33
02/23/17
06:33
Upgrade
AquaVenture rating change  »

AquaVenture upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

SAGE

SAGE Therapeutics

$61.93

-2.13 (-3.33%)

06:32
02/23/17
02/23
06:32
02/23/17
06:32
Hot Stocks
Breaking Hot Stocks news story on SAGE Therapeutics »

SAGE Therapeutics sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

SAGE

SAGE Therapeutics

$61.93

-2.13 (-3.33%)

06:31
02/23/17
02/23
06:31
02/23/17
06:31
Earnings
Breaking Earnings news story on SAGE Therapeutics »

SAGE Therapeutics reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

LB

Labarge

$58.13

0.43 (0.75%)

06:31
02/23/17
02/23
06:31
02/23/17
06:31
Recommendations
Labarge analyst commentary  »

L Brands selloff brings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

GE

General Electric

$30.09

-0.19 (-0.63%)

06:30
02/23/17
02/23
06:30
02/23/17
06:30
Periodicals
Suez in the running for General Electric's water unit, Reuters reports »

France's Suez is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

DLHC

DLH Holdings Corp.

$5.27

-0.08 (-1.50%)

06:30
02/23/17
02/23
06:30
02/23/17
06:30
Initiation
DLH Holdings Corp. initiated  »

DLH Holdings Corp.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CM

CIBC

$89.90

0.44 (0.49%)

06:28
02/23/17
02/23
06:28
02/23/17
06:28
Earnings
CIBC reports Q1 adjusted EPS C$2.89, consensus C$1.96 »

Reports Q1 loan loss…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMRE

Global Medical REIT

$8.48

0.06 (0.71%)

06:28
02/23/17
02/23
06:28
02/23/17
06:28
Initiation
Global Medical REIT initiated  »

Global Medical REIT…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TFX

Teleflex

$184.01

-0.51 (-0.28%)

06:25
02/23/17
02/23
06:25
02/23/17
06:25
Hot Stocks
Teleflex CEO Benson Smith retiring at end of 2017, succeeded by COO Liam Kelly »

Teleflex CEO Benson Smith…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

MBLY

Mobileye

$47.42

1.3 (2.82%)

06:22
02/23/17
02/23
06:22
02/23/17
06:22
Recommendations
Mobileye analyst commentary  »

Mobileye price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRI

Carter's

$83.58

-0.4 (-0.48%)

06:20
02/23/17
02/23
06:20
02/23/17
06:20
Hot Stocks
Carter's raises quarterly dividend 12% to 37c per share »

For payment on March 24…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

CRI

Carter's

$83.58

-0.4 (-0.48%)

06:19
02/23/17
02/23
06:19
02/23/17
06:19
Earnings
Carter's sees FY17 adjusted EPS growth 8%-10%, consensus $5.52 »

For fiscal 2017, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

CRI

Carter's

$83.58

-0.4 (-0.48%)

06:18
02/23/17
02/23
06:18
02/23/17
06:18
Earnings
Carter's sees Q1 adjusted EPS 80c-85c, consensus $1.14 »

For the first quarter of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

NVCR

Novocure

$7.15

-0.15 (-2.05%)

06:17
02/23/17
02/23
06:17
02/23/17
06:17
Hot Stocks
Novocure Chief Commercial Officer Peter Melnyk departing »

Novocure's Chief…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 02

    Mar

CS

Credit Suisse

$15.35

-0.13 (-0.84%)

06:17
02/23/17
02/23
06:17
02/23/17
06:17
Periodicals
Credit Suisse allocates $600M to expand Saudi Arabia business, Bloomberg says »

Credit Suisse is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

OUT

OUTFRONT Media

$26.89

-0.44 (-1.61%)

06:16
02/23/17
02/23
06:16
02/23/17
06:16
Downgrade
OUTFRONT Media rating change  »

OUTFRONT Media downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

CRI

Carter's

$83.58

-0.4 (-0.48%)

06:16
02/23/17
02/23
06:16
02/23/17
06:16
Hot Stocks
Breaking Hot Stocks news story on Carter's »

Carter's raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

EFOI

Energy Focus

$3.71

-0.21 (-5.36%)

06:16
02/23/17
02/23
06:16
02/23/17
06:16
Hot Stocks
Energy Focus sees Q1 restructuring charges of $1.1M »

As previously announced,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

CRI

Carter's

$83.58

-0.4 (-0.48%)

06:16
02/23/17
02/23
06:16
02/23/17
06:16
Earnings
Carter's reports Q4 adjusted EPS $1.79, consensus $1.67 »

Reports Q4 revenue $934M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

CMVT

Comverse

06:15
02/23/17
02/23
06:15
02/23/17
06:15
Periodicals
Former Comverse CEO faces sentencing in fraud case, Reuters reports »

Jacob "Kobi"…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFOI

Energy Focus

$3.71

-0.21 (-5.36%)

06:15
02/23/17
02/23
06:15
02/23/17
06:15
Recommendations
Energy Focus analyst commentary  »

Energy Focus reports Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.